DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Itacitinib

Generic Name: Itacitinib

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₂₃F_₄N_₉O

CAS Number: 1334298-90-6

Unique Ingredient Identifier: 19J3781LPM

Overview

Itacitinib has been used in trials studying the treatment of Melanoma, Carcinoma, Metastatic Cancer, Endometrial Cancer, and B-cell Malignancies, among others.

Background

Itacitinib has been used in trials studying the treatment of Melanoma, Carcinoma, Metastatic Cancer, Endometrial Cancer, and B-cell Malignancies, among others.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

Phase 1

Recruiting

Posted: 2023/04/21

Sponsor:Sidney Kimmel Compre...

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

Phase 2

Recruiting

Posted: 2023/03/07

Sponsor:H. Lee Moffitt Cance...

Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors

Phase 2

Withdrawn

Posted: 2022/12/21

Sponsor:

Douglas Johnson

Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease

Posted: 2022/09/30

Sponsor:Incyte Corporation

Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants

Phase 2

Recruiting

Posted: 2022/05/06

Sponsor:

City of Hope Medical...

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy